Scope
Description
The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL).
The required goods and services include:
• Provision of assay kits and reagents suitable for the intended patient population.
• Use of a software platform for analysis and reporting of results.
• Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows.
• Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components.
• Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing.
• Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information.
• Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required.
• MRD sensitivity threshold of 10-5 or lower
• Must work on DNA
• Performance data must be supported by evidence generated in relevant disease specific Clinical Trials
• Recognised technology included in clinical guidelines
• Ability to track clonal evolution
Contract 1. RMH clonoSEQ® Assay
Supplier
Contract value
- £1,158,208.33 excluding VAT
- £1,389,850 including VAT
Above the relevant threshold
Award decision date
22 December 2025
Standstill period
- End: 12 January 2026
- 8 working days
Earliest date the contract will be signed
15 January 2026
Contract dates (estimated)
- 20 January 2026 to 19 January 2031
- 5 years
Main procurement category
Goods
CPV classifications
- 33696500 - Laboratory reagents
Contract locations
- UKI - London
Procedure
Procedure type
Direct award
Supplier
Adaptive Biotechnologies Corporation
- Public Procurement Organisation Number: PBYH-2894-GJWD
1165 Eastlake Ave E, Seattle, United States
Seattle
WA 98109
United States
Email: dgalezowski@adaptivebiotech.com
Website: http://www.adaptivebiotech.com
Small or medium-sized enterprise (SME): Yes
Voluntary, community or social enterprise (VCSE): No
Supported employment provider: No
Public service mutual: No
Contract 1. RMH clonoSEQ® Assay
Contracting authority
The Royal Marsden NHS Foundation Trust
- Public Procurement Organisation Number: PXLT-9823-WVCY
Fulham Road
London
SW3 6JJ
United Kingdom
Region: UKI33 - Kensington & Chelsea and Hammersmith & Fulham
Organisation type: Public authority - central government
Other organisation
These organisations are carrying out the procurement, or part of it, on behalf of the contracting authorities.
Central London Community Healthcare NHS Trust
Summary of their role in this procurement: CLCH host a collaborative, outsourced procurement service - North West London Procurement Services.
- Public Procurement Organisation Number: PJXH-4297-MQQW
Ground Floor, 15 Marylebone Road
London
NW1 5JD
United Kingdom
Region: UKI32 - Westminster